179 related articles for article (PubMed ID: 31655348)
21. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
[TBL] [Abstract][Full Text] [Related]
22. Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities.
Shao JY; Yin WW; Zhang QF; Liu Q; Peng ML; Hu HD; Hu P; Ren H; Zhang DZ
Scand J Immunol; 2016 Sep; 84(3):182-90. PubMed ID: 27312286
[TBL] [Abstract][Full Text] [Related]
23. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell.
Bae DS; Hwang YK; Lee JK
Cell Immunol; 2012; 276(1-2):122-7. PubMed ID: 22613008
[TBL] [Abstract][Full Text] [Related]
24. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD.
Wiesmayr S; Webber SA; Macedo C; Popescu I; Smith L; Luce J; Metes D
Eur J Immunol; 2012 Feb; 42(2):541-50. PubMed ID: 22105417
[TBL] [Abstract][Full Text] [Related]
25. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
Bayigga L; Nabatanzi R; Sekiziyivu PN; Mayanja-Kizza H; Kamya MR; Kambugu A; Olobo J; Kiragga A; Kirimunda S; Joloba M; Nakanjako D
BMC Immunol; 2014 Jan; 15():2. PubMed ID: 24483185
[TBL] [Abstract][Full Text] [Related]
26. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
Vacca P; Martini S; Garelli V; Passalacqua G; Moretta L; Mingari MC
Eur J Immunol; 2013 Feb; 43(2):550-61. PubMed ID: 23192659
[TBL] [Abstract][Full Text] [Related]
27. The natural killer cell response to West Nile virus in young and old individuals with or without a prior history of infection.
Yao Y; Strauss-Albee DM; Zhou JQ; Malawista A; Garcia MN; Murray KO; Blish CA; Montgomery RR
PLoS One; 2017; 12(2):e0172625. PubMed ID: 28235099
[TBL] [Abstract][Full Text] [Related]
28. Soluble MICA in endometriosis pathophysiology: Impairs NK cell degranulation and effector functions.
Marin MLC; Rached MR; Monteiro SM; Kalil J; Abrao MS; Coelho V
Am J Reprod Immunol; 2024 Mar; 91(3):e13830. PubMed ID: 38454570
[TBL] [Abstract][Full Text] [Related]
29. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.
Mirjačić Martinović KM; Babović NLj; Džodić RR; Jurišić VB; Tanić NT; Konjević GM
Melanoma Res; 2014 Aug; 24(4):295-304. PubMed ID: 24769842
[TBL] [Abstract][Full Text] [Related]
30. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
31. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts.
Ward J; Bonaparte M; Sacks J; Guterman J; Fogli M; Mavilio D; Barker E
Blood; 2007 Aug; 110(4):1207-14. PubMed ID: 17513617
[TBL] [Abstract][Full Text] [Related]
32. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
33. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.
Schilling B; Halstead ES; Schuler P; Harasymczuk M; Egan JE; Whiteside TL
Cancer Immunol Immunother; 2012 Sep; 61(9):1395-405. PubMed ID: 22270713
[TBL] [Abstract][Full Text] [Related]
34. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
35. A rapid method for assessment of natural killer cell function after multiple receptor crosslinking.
Al-Hubeshy ZB; Coleman A; Nelson M; Goodier MR
J Immunol Methods; 2011 Mar; 366(1-2):52-9. PubMed ID: 21281644
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.
Castriconi R; Cantoni C; Della Chiesa M; Vitale M; Marcenaro E; Conte R; Biassoni R; Bottino C; Moretta L; Moretta A
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4120-5. PubMed ID: 12646700
[TBL] [Abstract][Full Text] [Related]
37. Celiac Disease-Related Inflammation Is Marked by Reduction of Nkp44/Nkp46-Double Positive Natural Killer Cells.
Marafini I; Monteleone I; Di Fusco D; Sedda S; Cupi ML; Fina D; Paoluzi AO; Pallone F; Monteleone G
PLoS One; 2016; 11(5):e0155103. PubMed ID: 27171408
[TBL] [Abstract][Full Text] [Related]
38. Increased expressions of NKp44, NKp46 on NK/NKT-like cells are associated with impaired cytolytic function in self-limiting hepatitis E infection.
Das R; Tripathy A
Med Microbiol Immunol; 2014 Oct; 203(5):303-14. PubMed ID: 24824867
[TBL] [Abstract][Full Text] [Related]
39. Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance.
Alter G; Jost S; Rihn S; Reyor LL; Nolan BE; Ghebremichael M; Bosch R; Altfeld M; Lauer GM
J Hepatol; 2011 Aug; 55(2):278-88. PubMed ID: 21168454
[TBL] [Abstract][Full Text] [Related]
40. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
